CALHM6 and neoplasm: Consequently, CALHM6 deficiency resulted in poor anti‐tumour immunity against IFN‐sensitive metastatic tumours and reduced efficacy of IFN‐dependent, poly(I:C)‐based immunotherapy (Kasamatsu et al, 2014).